Literature DB >> 18328810

Stationary phase induced alterations in mycobacterial RNA polymerase assembly: A cue to its phenotypic resistance towards rifampicin.

Raju Mukherjee1, Dipankar Chatterji.   

Abstract

Rapid emergence of multi-drug resistance in Mycobacterium tuberculosis has necessitated the development of newer candidate drugs which can selectively inhibit the growth of the organism. Among the best targets available today, transcription machinery is, by far, the most important one and the antibiotic rifampicin binds to a specific site on the enzyme RNA polymerase. However, it is not very effective towards the stationary phase of the organism or the persistors. In order to address this problem, we report here a protocol for generating an affinity tagged RNA polymerase, which can be purified easily from different phases of growth of the organism. It allows exploring RNAP associated proteins, which may confer resistance to rifampicin, using the approach of functional proteomics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18328810     DOI: 10.1016/j.bbrc.2008.02.118

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Sigma factor F does not prevent rifampin inhibition of RNA polymerase or cause rifampin tolerance in Mycobacterium tuberculosis.

Authors:  Ruben C Hartkoorn; Claudia Sala; Sophie J Magnet; Jeffrey M Chen; Florence Pojer; Stewart T Cole
Journal:  J Bacteriol       Date:  2010-08-20       Impact factor: 3.490

2.  Distinct and contrasting transcription initiation patterns at Mycobacterium tuberculosis promoters.

Authors:  Priyanka Tare; Arnab China; Valakunja Nagaraja
Journal:  PLoS One       Date:  2012-09-07       Impact factor: 3.240

3.  A transcript cleavage factor of Mycobacterium tuberculosis important for its survival.

Authors:  Arnab China; Sonakshi Mishra; Valakunja Nagaraja
Journal:  PLoS One       Date:  2011-07-08       Impact factor: 3.240

4.  Co-evolution of RNA polymerase with RbpA in the phylum Actinobacteria.

Authors:  Abhinav Dey; V R Adithi; Dipankar Chatterji
Journal:  Appl Transl Genom       Date:  2012-05-26

5.  Mode of Action of Kanglemycin A, an Ansamycin Natural Product that Is Active against Rifampicin-Resistant Mycobacterium tuberculosis.

Authors:  Hamed Mosaei; Vadim Molodtsov; Bernhard Kepplinger; John Harbottle; Christopher William Moon; Rose Elizabeth Jeeves; Lucia Ceccaroni; Yeonoh Shin; Stephanie Morton-Laing; Emma Claire Louise Marrs; Corinne Wills; William Clegg; Yulia Yuzenkova; John David Perry; Joanna Bacon; Jeff Errington; Nicholas Edward Ellis Allenby; Michael John Hall; Katsuhiko S Murakami; Nikolay Zenkin
Journal:  Mol Cell       Date:  2018-09-20       Impact factor: 17.970

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.